Navigation Links
Telik Announces Preclinical Presentations at AACR Annual Meeting
Date:4/14/2009

PALO ALTO, Calif., April 14 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced today that two abstracts highlighting results from its Research and Development programs will be presented at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver, CO.

Details of the presentations are as follows:

  • In vivo Characterization and Mechanism of Action of Orally Active Aurora Kinase/VEGFR Inhibitors; Sunday, April 19, 2009, 1:00 - 5:00pm; Kinase Inhibitors 1; Abstract # 1764
  • Anti-Tumor Efficacy and Molecular Mechanism of TLK58747; Tuesday, April 21, 2009, 1:00 -- 5:00pm; Agents Causing DNA Damage or Proteasome Inhibition; Abstract # 4515

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. Telik Announces Preclinical Presentations at AACR Annual Meeting
3. Telik Announces Patents on Compounds Related to TELINTRA
4. Telik Announces Year-End Financial Release, Conference Call and Webcast
5. Telik Announces Fourth Quarter and 2008 Year End Financial Results and 2009 Financial Guidance
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently ... Talei has come up with a proprietary technique that he calls the AuraLyft ... have dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... Georgia (PRWEB) , ... June 23, 2017 , ... ... Negative Breast Cancer Conference from Sept. 18 to 20. , The two-day conference ... (TNBC) subtype with the goal of improving patients’ lives and eliminating racial breast ...
(Date:6/23/2017)... Beach, FL (PRWEB) , ... June 23, 2017 , ... ... in Pinecrest, Florida. This is MD Now’s 28th facility overall and marks the urgent ... Dixie Highway, located one mile North of The Falls shopping mall. The new clinic ...
(Date:6/23/2017)... ... 2017 , ... Ross Insurance Agency ( http://www.rossinsuranceagency.com ) saves ... Agency’s (FEMA) recent update of flood zones, more people than ever are in ... enacted to reflect the actual risk in flood zone areas during a time ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... Ulster University, ... June, 2017 from 9 am to 3 pm to present to graduate students exciting ... is an original curriculum project led by The Health Improvement Service of the ...
Breaking Medicine News(10 mins):
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
(Date:6/9/2017)... June 9, 2017 AirXpanders, Inc. (ASX: AXP) ... the design, manufacture, sale and distribution of the AeroForm® ... progress of its commercial roll-out in the ... more than one hundred (100) medical institutions and health ... offers a needle-free alternative for women who choose reconstructive ...
(Date:6/8/2017)...  Less than a month ago, amateur hackers executed ... including hospital networks, in over 150 countries. ... largest online extortion attempts ever recorded. With the increasing ... imperative that providers understand where the risks lie, and ... and many other very real cyber threats.  ...
Breaking Medicine Technology: